UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day (read more)
UTHSC
UTHSC Researchers Play Role in Supporting Development of COVID-19 Vaccines
To reduce the risk to workers developing and testing the COVID-19 vaccine, Pfizer-BioNTech and other companies have utilized a surrogate system, one of which was developed in the laboratory of Michael Whitt, PhD, a UTHSC virologist and UTRF innovator. Story written by Peggy Reisser, UTHSC Researchers at the University of Tennessee Health Science Center have (read more)
UTRF Welcomes James Parrett
The University of Tennessee Research Foundation (UTRF) is pleased to announce that James Parrett has joined the organization as a Technology Manager at its Memphis office. At UTRF, James will be involved in all aspects of the technology transfer process, including building relationships with research groups across the University of Tennessee Health Science Center campus (read more)